Forbion to focus record €460M fund on early-stage opportunities

Increased deal flow across the board has led Forbion to split its funds between early and late-stage opportunities, with its latest €460 million ($557.7 million) fund, which closed this week, focused on the former. 

“We invested Forbion III and IV across the spectrum of stages from preclinical to Phase III, but given the sharp increase we’ve seen in late-stage deals in Phase IIb and Phase III, we decided to single those out and raise a separate fund in July focused on those late-stage opportunities. Those are no longer part of the strategy of Forbion V,” said Forbion Capital Partners’ Sander Slootweg. ...